GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (FRA:NB3) » Definitions » Issuance of Debt

Neurocrine Biosciences (FRA:NB3) Issuance of Debt : €0 Mil (TTM As of Dec. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Issuance of Debt?

Neurocrine Biosciences's Issuance of Debt for the three months ended in Dec. 2024 was €0 Mil.

Neurocrine Biosciences's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 was €0 Mil.


Neurocrine Biosciences Issuance of Debt Historical Data

The historical data trend for Neurocrine Biosciences's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Issuance of Debt Chart

Neurocrine Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Neurocrine Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Neurocrine Biosciences Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurocrine Biosciences Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences Business Description

Traded in Other Exchanges
Address
6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Neurocrine Biosciences Headlines

No Headlines